Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five ratings firms that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have covered the stock in the last year is $27.80.

A number of research firms have weighed in on CPRX. TheStreet upgraded shares of Catalyst Pharmaceuticals from a "c+" rating to a "b" rating in a research report on Tuesday, March 12th. Citigroup began coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a "buy" rating and a $27.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating and set a $34.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. HC Wainwright restated a "buy" rating and set a $26.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Monday, June 3rd. Finally, Oppenheimer reiterated an "outperform" rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 5,333 shares of the company's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $16.30, for a total value of $86,927.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Richard J. Daly sold 17,323 shares of the company's stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $15.97, for a total value of $276,648.31. Following the completion of the sale, the chief executive officer now owns 234,824 shares of the company's stock, valued at $3,750,139.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Molly Harper sold 5,333 shares of the company's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $16.30, for a total transaction of $86,927.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,197 shares of company stock valued at $1,777,560. 11.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CPRX. Parkside Financial Bank & Trust purchased a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $31,000. GAMMA Investing LLC boosted its stake in shares of Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 819 shares during the period. CWM LLC boosted its stake in shares of Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 3,549 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 306.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company's stock valued at $85,000 after purchasing an additional 3,829 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Catalyst Pharmaceuticals by 84.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company's stock valued at $104,000 after purchasing an additional 2,833 shares during the period. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX traded down $0.15 during trading hours on Wednesday, hitting $15.46. The stock had a trading volume of 502,306 shares, compared to its average volume of 1,338,985. The firm has a 50-day moving average price of $15.66 and a 200 day moving average price of $15.39. Catalyst Pharmaceuticals has a fifty-two week low of $11.55 and a fifty-two week high of $17.50. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 28.63, a PEG ratio of 1.43 and a beta of 0.71.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, hitting analysts' consensus estimates of $0.31. The company had revenue of $98.51 million during the quarter, compared to analysts' expectations of $97.24 million. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. As a group, analysts predict that Catalyst Pharmaceuticals will post 1.63 EPS for the current fiscal year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.